Sarepta Therapeutics
SRPT
$118.59
Share price
-2.17%
Change (1 day)
23.39%
Change (1 year)
Categories
Sarepta Therapeutics is an American medical research company dedicated to the discovery and development of precisely effective gene therapeutics for the treatment of rare neuromuscular diseases.
P/S ratio for Sarepta Therapeutics (SRPT)
P/S ratio as of October 2023 (TTM): 11.0
According to Sarepta Therapeutics 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 11.0241. At the end of 2023 the company had a P/S ratio of 10.6.
P/S ratio history for Sarepta Therapeutics from 2001 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 10.6 | -12.8% |
| 2022 | 12.2 | 9.13% |
| 2021 | 11.2 | -55.15% |
| 2020 | 24.9 | -2.22% |
| 2019 | 25.5 | -1.12% |
| 2018 | 25.8 | 10.75% |
| 2017 | 23.3 | -91.58% |
| 2016 | 276 | -80.34% |
| 2015 | > 1000 | 2193.16% |
| 2014 | 61.3 | 13.28% |
| 2013 | 54.1 | 146.82% |
| 2012 | 21.9 | 918.16% |
| 2011 | 2.15 | -73.42% |
| 2010 | 8.10 | -11.75% |
| 2009 | 9.17 | 316.5% |
| 2008 | 2.20 | -73.37% |
| 2007 | 8.27 | -99.44% |
| 2006 | > 1000 | 3874.02% |
| 2005 | 36.9 | -81.29% |
| 2004 | 197 | 36.42% |
| 2003 | 145 | -8.87% |
| 2002 | 159 | -55.81% |
| 2001 | 359 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Gilead Sciences GILD | 3.37 | -69.41% | 🇺🇸 USA |
 PTC Therapeutics
PTCT | 1.95 | -82.27% | 🇺🇸 USA |
 Novavax NVAX | 0.4967 | -95.49% | 🇺🇸 USA |
 Alnylam Pharmaceuticals
ALNY | 18.1 | 63.99% | 🇺🇸 USA |
 Insmed INSM | 13.5 | 22.81% | 🇺🇸 USA |
 BioCryst Pharmaceuticals
BCRX | 4.18 | -62.05% | 🇺🇸 USA |
 Avidity Biosciences RNA | 44.9 | 307.39% | 🇺🇸 USA |